Cervical cancer

Nov 08, 2024

Cervical cancer remains a leading cause of death among women worldwide. While increased awareness and early diagnosis have significantly reduced fatalities over the years, the risk is still substantial. A major factor in the development of cervical cancer is persistent infection with Human Papillomavirus (HPV), whi...

Nov 08, 2024

Over the past two decades, the majority of countries in the 7MM have experienced a decrease in cervical cancer cases. In the United States, incidence rates declined from the mid-1970s to the mid-2000s, partly attributed to increased screening efforts.  Cervical cancer is most often diagnosed between the age...

Nov 08, 2024

Cervical cancer stands as the fourth most diagnosed cancer among women globally, trailing breast, colorectal, and lung cancers. However, its impact is disproportionately heavy on developing nations, where prevalence rates soar. In 2022, WHO estimated approximately 660,000 new cases of cervical cancer and 350,000 de...

Nov 08, 2024

Human papillomavirus (HPV) is a very commonly found virus, and most people have experienced it at some point in their lives. There are almost 200 different strains that can be split into low-risk and high-risk. Low-risk HPV usually doesn’t cause many problems, it usually causes conditions like genital warts. Wherea...

Nov 07, 2024

Cervical cancer is the fourth most common type of cancer and the fourth leading cause of death in women. According to the WHO, HPV infections contribute to an estimated 530,000 cases of cervical cancer and 264,000 related deaths annually, with over 85% of these fatalities occurring in low- and middle-income countri...

May 07, 2024

Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia  Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular is...

Feb 07, 2024

As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...

Jan 16, 2024

Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure Merck, also recognized as MSD in regions beyond the United States and Canada, has officially announced that the FDA has approved for the use of KEYTRUDA, Merck's anti-PD-1 therapy, in conjunction with chemoradiotherapy (CRT) for treatin...

Nov 29, 2022

C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...

Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...